Earnings ·
Vericel raises full-year revenue guidance to $344-$346M as Q3 net income jumps 179% to $14.2 Million
VCELVericel Corp
Vericel reported third-quarter total net revenue of $85.4 million, a 26% increase from the prior year period, driven by strong growth in its MACI and Burn Care segments. Net income surged 179% to $14.2 million, or $0.27 per diluted share, while adjusted EBITDA rose 48% to $25.2 million with a margin of 30%. The company raised its full-year revenue guidance to $344-$36 million and increased its adjusted EBITDA margin outlook to 28%, citing strong commercial momentum in MACI and NexoBrid. Vericel operates as a provider of advanced cell therapies and specialty biologics for sports medicine and severe burn care markets.